BERGEM·HEALTH
Home Doctors Prof. MD. Nuri Faruk Aykan
MEDICAL ONCOLOGY · LIV BAHÇEŞEHİR

Prof. MD. Nuri Faruk Aykan

Professor of Medical Oncology · İSÜ Liv Hospital Bahçeşehir
Prof. Dr. Nuri Faruk Aykan is a senior medical oncologist at İSÜ Liv Hospital Bahçeşehir, with a career spanning Ankara University, Ondokuz Mayıs University and the Oncology Institute of Istanbul University. He completed research fellowships at Université Louis Pasteur in Strasbourg (molecular genetics, 1981) and Hôtel-Dieu de Paris (cell culture, 1991). His clinical focus covers colorectal, gastric, pancreatic and neuroendocrine cancers, with active membership in ASCO, ESMO and ESDO. He led the prize-winning KOLONTÜRK colorectal cancer study (2013).
Specialties: Oncology
45+
years in medicine
3
international research fellowships
Colorectal CancerGastric CancerPancreatic CancerNeuroendocrine TumoursImmunotherapyASCO MemberESMO MemberESDO Member
A BergemHealth coordinator arranges contact with the professor within 24–48 hours on business days.
Direct contract with BergemHealth
CONSULTATION LANGUAGES
TR Turkish · native
EN English · professional
FR French · professional
RU Russian · via BergemHealth coordinator
UK Ukrainian · via BergemHealth coordinator
ISTANBUL · 06/2026
AWARDS & RECOGNITION
  • 2013
    First Prize (KOLONTÜRK Study)
    Turkish Cancer Research and Warfare Organization 20th National Cancer Congress
  • 1976
    Graduation 1st Prize
    Ankara University Faculty of Medicine
  • 1970-1976
    TÜBİTAK unrequited university scholarship
    TÜBİTAK
EDUCATION & CAREER

Timeline

Career milestones.

current
Professor of Medical Oncology
İSÜ Liv Hospital Bahçeşehir
PUBLICATIONS

Scientific work

Selected peer-reviewed publications.

  • 2015
    Int J Cancer
    «Red meat subtypes and colorectal cancer risk»
    · first author
  • 2015
    Oncol Rev
    «Red Meat and Colorectal Cancer»
    · first author
  • 2020
    BMJ Open
    «Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey»
    · co-author
  • 2020
    World J Clin Oncol
    «Objective response rate assessment in oncology: Current situation and future expectations»
    · first author
  • 2022
    Future Oncol
    «Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer»
    · co-author
  • 2019
    J Gastrointest Cancer
    «Bevacizumab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients»
    · co-author
REQUEST

Tell me about your case — I’ll read it personally.

Fill in the short form on the consultation page — diagnosis, preferred timing, attached records. We assemble a tumour board for your case and reply within 4 hours.

Open the consultation form
  • Reply within 4 hours during business hours
  • Confidentiality guaranteed
  • Coordinator-translator inside the doctor’s office
  • Tumour board of 2–3 professors within 72 hours